JPRN-UMIN000016255已完成2 期
Phase II clinical study of nab-PTX/CBDCA (administer 3-weeks on / 1-week off) for patients with clinical stage IIIB/IV or recurrent NSCLC - Phase II clinical study of nab-PTX/CBDCA for patients with clinical stage IIIB/IV or recurrent NSCLC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.With severe myelosuppression. 2.With the history of hypersensitivity for nab-paclitaxel or CBDCA. 3.With active double cancer. 4.With active infectious disease:temperature=>38 5.With clinically important complications. 6.Interstitial pneumonia or pulmonary fibrosis on chest X-rays. 7.Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 8.Accepted continuous use of steroid. 9.Physician concludes that the patient's participation in this trial is inappropriate.
研究者
相似试验
招募中
不适用
Phase II study of the 2nd line Nab-PTX/CBDCA combination therapy for advanced non-small cell lung cancer which is previously treated with platinum-based chemotherapyon-small cell lung cancerJPRN-UMIN000011669Dokkyo Medical University40
已完成
不适用
Phase2 study of dose dense EC followed Nab-PTXas neoadjuvant chemotherapy for HER2-negative primary breast cancerbreast cancerJPRN-UMIN000020693Kyoto Prefectural University of Medicine50
已完成
2 期
A phase II study of CBDCA and TS-1 in patients with advanced non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000001746Gunma University Hospital35
已完成
2 期
Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of LungCarcinoma, Non-Small-Cell LungNCT01236716Chinese Society of Lung Cancer126
已完成
2 期
BTRX-246040 Study in Participants With Parkinson's Disease With Motor FluctuationsMotor DisorderParkinson DiseaseNCT03608371BlackThorn Therapeutics, Inc.24